NSE: GLAXO | BSE: 500660

Mid-range Performer

Download real time

2770.30 -81.50 (-2.86%)

44.21% Gain from 52W Low

66,800 NSE+BSE Volume

NSE 05 Sep, 2025 3:31 PM (IST)

46,930.5

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

24 Aug 2022

2770.30

-2.86%

Analyst call highlights

Hold: GlaxoSmithKline Pharmaceut...

ICICI Securities Limited

Company believes its key brands and therapies would continue to grow. It has been able to maintain its market share in key brands and expects to improve on it gradually.

GlaxoSmithKline Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

GlaxoSmithKline Pharmaceuticals Ltd.

26 Jul 2022

2770.30

-2.86%

Pain and vaccine therapies hinder revenue growth???

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd. is trading below its 30 day SMA of 2848.8

GlaxoSmithKline Pharmaceuticals Ltd.

16 May 2022

2770.30

-2.86%

Muted 4QFY22; focus remains on key brands to revitalize growth

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd. is trading above its 200 day SMA of 2708.3

GlaxoSmithKline Pharmaceuticals Ltd.

14 Mar 2022

2770.30

-2.86%

GlaxcoSmithKline Pharmaceuticals Ltd- Report

Buy: GlaxoSmithKline Pharmaceut...

Joindre Capital Services

Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

07 Feb 2022

2770.30

-2.86%

Product mix drives profitability

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO) delivered in-line 3QFY22 earnings after including profits from discontinued operations. While the pharma portfolio tracked doubledigit growth, it was offset to some extent by the lower off-take of vaccines because of the third COVID wave. With COVID receding, we expect a gradual revival in the vaccine business. We have tweaked our EPS estimates for FY22/FY23/24 by 2% to factor in :a) an improved outlook for the vaccine business, b) a better traction in brands...

Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

30 Oct 2021

2770.30

-2.86%

Favourable demand/Superior execution drives earnings growth

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GLXO's 2QFY22 performance was better than our expectations due to a healthy revival in the anti-infective/derma segment, coupled with improved operating leverage. In particular, Augmentin and Calpol regained their place among the top five brands in the Indian Pharmaceuticals Market (IPM). The...

GlaxoSmithKline Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

GlaxoSmithKline Pharmaceuticals Ltd.

27 Jul 2021

2770.30

-2.86%

Below expectations as margins disappoint; cut estimates 8 %/7 %

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Revenue grew 22% YoY to INR7.9b (est. INR8.1b), led by Dermatology, AntiInfectives, and Pain/Analgesics segment. Gross margin expanded by 40bp YoY to 61.7% due to better product mix. EBITDA margin expanded at a higher rate (160bp YoY) to 19% (est. 21.5%) due to better operating leverage, with lower employee cost (down 220bp YoY as a percentage of sales), partially offset by higher other opex (+100bp...

GlaxoSmithKline Pharmaceuticals Ltd. has lost -20.08% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2021

2770.30

-2.86%

Dermatology outshines, while Anti-Infectives drags down 4Q

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO)'s 4QFY21 performance was marginally below estimates, largely led by moderate YoY sales growth for the quarter. Based on AIOCD data, strong growth in the Dermatology segment was offset by a weak performance from the Anti-Infectives and Pain Analgesics segments. We raise our EPS estimates by 6%/7% for FY22E/FY23E, factoring in a) a robust outperformance from Dermatology, b) strong revival in AntiInfectives, Pain Analgesics, and Vitamins/Minerals/Nutrients, partly supported by the opportunity arising from COVID. We continue to value GLXO at 38x 12M forward earnings (25% discount to its three-year average)...

GlaxoSmithKline Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

GlaxoSmithKline Pharmaceuticals Ltd.

07 Feb 2021

2770.30

-2.86%

Better operating leverage drives profitability

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO)'s 3QFY21 performance was better than estimated, with an increase in sales driving higher profitability (on account of operating leverage). With the intensity of YoY decline lower over the past two quarters, GLXO exhibited low-double-digit YoY growth with the easing of the lockdown and partly aided by the low base of the past year. We increase our EPS estimates by 8%/3%/2% for FY21/FY22/FY23E, factoring in strong recovery in key therapies and improving productivity. We continue to value GLXO at 38x 12M forward earnings (25% discount to its...

Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

31 Jul 2020

2770.30

-2.86%

GlaxoSmithKline Pharmaceuticals Ltd

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.

GlaxoSmithKline Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Is GlaxoSmithKline Pharmaceuticals Ltd. worth buying?

124 Votes:

Buy 66.13%

Sell 20.97%

Hold 12.9%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf